Lumos Diagnostics has today announced that U.S. FDA has granted 510(k) clearance with CLIA waiver for FebriDx®, enabling broader use across frontline healthcare settings and significantly expanding its commercial opportunity.

Original from: PR Newswire Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the cobas® c 703 and cobas® ISE neo. As part of the..

Original from: AmoyDx Amoy Diagnostics Co., Ltd., Medical ＆ Biological Laboratories Co., Ltd., a group company of Tokuyama Corporation, and Precision Medicine Asia Co., Ltd. today announced that MBL rec..

Original from: PR Newswire Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spect..

We are excited to announce the 1st Global IVD Innovation Summit, taking place during CACLP 2026 in Xiamen! 🌍 📅 Date & Time: March 22, 2026 | 14:30–17:30 (GMT+8) Themed ..

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025.

Diasorin (FTSE MIB: DIA) today announces the U.S. FDA approval of the LIAISON QuantiFERON-TB Gold Plus II assay as a next-generation automated Interferon Gamma Release Assay (IGRA) designed in partnership with QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) to enhance laboratory productivity, workflow efficiency and turnaround time for latent tuberculosis infection (LTBI) testing in the United States.

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced that a broad portfolio of its Alethia molecular assays has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.

Automatic blood grouping analyzer is an analyzer that can forward and reverse ABO blood group, Rh (D) blood group test, irregular antibody screening and cross-matching of blood test. It mainly consists of liquid handl..

Guardant Health has acquired MetaSight Diagnostics for $59 million in upfront cash to bolster its multi-disease detection pipeline, the company said Thursday. The deal includes up to $90 million in payments tied to future commercial performance and regulatory approvals.

Merck (MRK.N), opens new tab said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent expiry of the blockbuster treatment.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.

Wantai Biopharm Advances Hepatitis B Virus Detection Technology and Chronic Disease POCT Diagnostic System Construction Recently, Wantai Biopharm was officially awarded the "R&D and Ap..

According to information released at the 2026 National Medical Device Supervision and Administration Work Conference, China continued to strengthen innovation and industrial upgrading in the medical device sector in 2025, achieving steady and sustained progress.

Waters Corporation (NYSE: WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE: BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies, and an industry-leading financial outlook. The Company also announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors (the "Waters Board"), increasing the size of the Waters Board to a total of 11 members.